FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

AbbVie Cancer Drug Approved for CDF Coverage in UK

Oct. 12, 2017

UK drug regulators approved venetoclax for coverage through the Cancer Drugs Fund of the National Health Service.

The drug is marketed by AbbVie as Venclyxto.

Venclyxto was approved for treating chronic lymphocytic leukemia in adults.

View today's stories